U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06843239) titled 'Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)' on Feb. 07.
Brief Summary: The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Study Start Date: Feb. 06
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis (SSc)
Scleroderma
Intervention:
BIOLOGICAL: Tibulizumab
Anti BAFF/IL-17 antibody
OT...